TreatmentTrends®: Prostate Cancer Q2 2015 (US) is part of a series of reports that examine current trends in the management of localized to metastatic prostate cancer from the perspective of both urologists and medical oncologists. TreatmentTrends® are syndicated reports that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. These reports evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.
Questions Answered in This Report:
- Assess current and anticipated prescribing of old and new hormonal agents and chemotherapies to metastatic castrate-resistant prostate cancer (mCRPC) patients. How does prescribing of currently available therapies differ by patients’ symptomatic status and by line of therapy? How is prescribing anticipated to change over the next year?
- Assess how the importance and performance of various attributes (e.g., efficacy, safety, dosing) differ between products. For example, how important is rapid reduction of PSA or having a minimal impact on quality of life in hormone-sensitive prostate cancer, according to surveyed physicians? How do currently marketed products, such as Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s Zytiga (abiraterone), Medivation/Astellas Pharma’s Xtandi (enzalutamide), and Bayer HealthCare’s Xofigo (radium-223), perform in terms of pain palliation, delaying time to progression, and improving overall survival in mCRPC patients?
- Assess sales representative contact frequency and physician message recall between products. When was the last time a sales representative visited physicians for the various current therapies? What percentages of physicians were visited in the past month, and what messages were recalled by brand?
- Understand medical oncologists’ perception of late-phase prostate cancer therapies, including awareness of and familiarity with products in late-phase development. The report covers approximately ten products in late-phase development. Which drug characteristics do surveyed physicians perceive to be the most important attributes for mCRPC therapies? How do surveyed urologists and medical oncologists rank future CRPC treatments (including new hormonal agents and therapeutic vaccines)?
Markets covered: United States.
Primary research: 48 urologists and 50 medical oncologists.
Indication coverage: Prostate cancer.